Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
A study analyzed how well people with HIV and their health care providers can navigate the experimental long-acting injectable Cabenuva.
Long-acting injectable cabotegravir for HIV prevention could hit the market for men and women in early 2022.
Cabotegravir injections given every eight weeks as PrEP are even more effective than daily Truvada.
The HIV advocacy group has been assiduously tracking PrEP data for five years.
We asked participants and presenters at the #AIDS2020Virtual what was compelling to them about the gathering. Here are their responses.
The placebo-controlled trial compared injections of cabotegravir given every eight weeks versus daily Truvada as PrEP.
The injectable cabotegravir, given every eight weeks, is just as effective as daily Truvada for HIV prevention.
A clinical trial compared injectable cabotegravir given every eight weeks versus daily Truvada for HIV prevention.
For the first time, researchers are assessing a pairing of a long-acting antiretroviral and a long-acting antibody.
Here are the HIV treatment news stories with the most views this year.
Long-acting injectables may be given once every other month, according to new findings.
As long-acting injectables near approval, daily pill versions of the same drugs show long-term benefit.
Cabotegravir plus rilpivirine maintenance therapy worked equally well when taken monthly or every two months.
Recently, ViiV Healthcare applied for approval of the first long-acting injectable HIV regimen.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.